Allograft Tolerance Study (ALLTOL)

About This Study

For organ transplant recipients, anti-rejection medications known as “immunosuppressive drugs” help prevent the immune system from attacking the foreign organ and causing damage. Although this helps keep the organ healthy, anti-rejection medications have a number of serious side effects including an increased risk of infections and certain kinds of cancer.

Some individuals who receive organ transplants are able to come off of all immune-suppressing medications without rejecting their organ. This is called “tolerance.”

The goal of the ALLTOL Study is to follow tolerant transplant recipients to learn:

  • How long liver or kidney transplant recipients can remain tolerant
  • What happens in the tolerant recipient’s body over time
  • If there are patterns in the body that are linked to tolerance

This study is observational, meaning there are no study medications or procedures. 

Study participation will last for up to five years, and will require 1 study visit per year. These visits will include:

  • Overall health assessment
  • Blood and urine collections

If you cannot travel to a study site, the study site staff will discuss your health status by phone and arrange for a nurse to come to your location to collect the research specimens.

The study will run until January 31, 2021.  Study participation will last for the amount of time left in the study at the time of enrollment (up to 5 years).

Do you Qualify for this Clinical Trial?

To learn more about this study and whether you are eligible to participate, please visit the study website: ALLTOL.org.

Principal Investigator

Laurence Turka, MD | Massachusettes General Hospital | Boston, MA

Locations

University of California, San Francisco|San Francisco, CA
Emory University School of Medicine|Atlanta, GA
Ann & Robert H. Lurie Chidren's Hospital of Chicago|Chicago, IL
University of Pennsylvania Medical Center|Philadelphia, PA
Children's Hospital of Pittsburgh|Pittsburgh, PA

Contact a study site near you.